Literature DB >> 2995074

Adrenergic modulation of vascular prostacyclin (PGI2) secretion.

J Y Jeremy, D P Mikhailidis, P Dandona.   

Abstract

An in vitro model for the study of adrenoreceptor-prostacyclin (PGI2) relationships in the rat aorta is described. PGI2 synthesis was stimulated by adrenergic agonists (rank order of potency: epinephrine greater than norepinephrine greater than phenylephrine greater than methoxamine). Isoproterenol, UK 14304, clonidine and salbutamol were without effect. Epinephrine (3 X 10(-7) M)-stimulated PGI2 synthesis was inhibited by adrenoreceptor antagonists (rank order of potency: yohimbine greater than prazosin greater than phentolamine greater than corynanthine much greater than propranolol). The absence of calcium in incubation media abolished epinephrine-stimulated PGI2 synthesis as did the calcium channel blocker, verapamil, in a dose-dependent manner. Calcium ionophore A23187 (10(-5) M)-stimulated PGI2 synthesis was inhibited by verapamil (in a dose-dependent manner), but not by prazosin, phentolamine or yohimbine. It is concluded that epinephrine-mediated rat aortic PGI2 synthesis is alpha-adrenoceptor- and not beta-adrenoceptor-mediated, calcium-dependent, and that the alpha-adrenoceptor antagonists evaluated do not have verapamil-like calcium channel blocking activities. These findings may be relevant to contraction-relaxation cycles of vascular tissue.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2995074     DOI: 10.1016/0014-2999(85)90517-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  14 in total

1.  Effect of alpha a-adrenoceptor antagonist on platelet activation during insulin-induced hypoglycaemia in type 2 (non-insulin-dependent) diabetes mellitus.

Authors:  D P Mikhailidis; M A Barradas; J Y Jeremy; P Dandona
Journal:  Diabetologia       Date:  1989-02       Impact factor: 10.122

2.  The effect of nifedipine, nimodipine and nisoldipine on agonist- and trauma-stimulated vascular prostacyclin synthesis in vitro.

Authors:  J Y Jeremy; D P Mikhailidis; P Dandona
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-01       Impact factor: 3.000

3.  Effects of verapamil and nisoldipine on human platelets: in vivo and in vitro studies.

Authors:  J Y Jeremy; M A Barradas; D P Mikhailidis; P Dandona
Journal:  Br J Clin Pharmacol       Date:  1986-08       Impact factor: 4.335

Review 4.  The zone diet and athletic performance.

Authors:  S N Cheuvront
Journal:  Sports Med       Date:  1999-04       Impact factor: 11.136

5.  Actions of amiloride analogues on prostacyclin synthesis by rat aortic rings.

Authors:  J M Ritter; A Aksoy; E J Cragoe; G W Taylor
Journal:  Br J Pharmacol       Date:  1987-12       Impact factor: 8.739

6.  Differential changes of adrenoceptor- and muscarinic receptor-linked prostacyclin synthesis by the aorta and urinary bladder of the diabetic rat.

Authors:  J Y Jeremy; C S Thompson; D P Mikhailidis
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

7.  pH-dependent stimulation by Ca2+ of prostacyclin synthesis in rat aortic rings: effects of drugs and inorganic ions.

Authors:  J M Ritter; C E Frazer; G W Taylor
Journal:  Br J Pharmacol       Date:  1987-06       Impact factor: 8.739

8.  Differential regional changes of prostacyclin and thromboxane A2 synthesis in the intestinal tract of the fasted and semistarved rat.

Authors:  J Y Jeremy; C S Thompson; P Dandona
Journal:  Pflugers Arch       Date:  1987-01       Impact factor: 3.657

9.  The iron chelators desferrioxamine and 1-alkyl-2-methyl-3-hydroxypyrid-4-ones inhibit vascular prostacyclin synthesis in vitro.

Authors:  J Y Jeremy; G J Kontoghiorghes; A V Hoffbrand; P Dandona
Journal:  Biochem J       Date:  1988-08-15       Impact factor: 3.857

10.  Angiotensin converting enzyme inhibitors (captopril, CGS14831 and CGS14824A) antagonise in vitro smooth muscle prostanoid synthesis: evidence for calcium channel blockade.

Authors:  J Y Jeremy; D P Mikhailidis; P Dandona
Journal:  Agents Actions       Date:  1988-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.